Loading clinical trials...
Loading clinical trials...
A Phase 1/2, Multi-Center, Open-Label, Dose-Finding Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of BMS-986458, Alone and in Combination With Anti-lymphoma Agents in Participants With Relapsed/Refractory Non-Hodgkin Lymphomas (R/R NHL)
Conditions
Interventions
BMS-986458
Rituximab
+2 more
Locations
65
United States
Mayo Clinic in Arizona - Phoenix
Phoenix, Arizona, United States
City of Hope Comprehensive Cancer Center
Duarte, California, United States
Local Institution - 0068
Jacksonville, Florida, United States
Moffitt Cancer Center
Tampa, Florida, United States
Local Institution - 0014
Fairway, Kansas, United States
Dana-Farber Cancer Institute
Boston, Massachusetts, United States
Start Date
December 29, 2023
Primary Completion Date
October 28, 2027
Completion Date
October 28, 2028
Last Updated
April 14, 2026
BMS Clinical Trials Contact Center www.BMSClinicalTrials.com
CONTACT
855-907-3286Clinical.Trials@bms.comFirst line of the email MUST contain NCT # and Site #.
CONTACT
Lead Sponsor
Bristol-Myers Squibb
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions